BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 30030708)

  • 21. Adjuvant endocrine therapy for breast cancer.
    Rao RD; Cobleigh MA
    Oncology (Williston Park); 2012 Jun; 26(6):541-7, 550, 552 passim. PubMed ID: 22870539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer.
    Van Asten K; Poppe A; Punie K; Jongen L; Lintermans A; Wildiers H; Neven P
    Curr Treat Options Oncol; 2015 Jul; 16(7):31. PubMed ID: 26031545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adherence to long-term adjuvant hormonal therapy for breast cancer.
    Gotay C; Dunn J
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-15. PubMed ID: 22098287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adherence to adjuvant endocrine therapy: is it a factor for ethnic differences in breast cancer outcomes in New Zealand?
    Seneviratne S; Campbell I; Scott N; Kuper-Hommel M; Kim B; Pillai A; Lawrenson R
    Breast; 2015 Feb; 24(1):62-7. PubMed ID: 25486877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Age-related differences in persistence in women with breast cancer treated with tamoxifen or aromatase inhibitors in Germany.
    Jacob L; Hadji P; Kostev K
    J Geriatr Oncol; 2016 May; 7(3):169-75. PubMed ID: 27091510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical consultations and investigations before and after discontinuation of endocrine therapy in women with primary breast cancer.
    Lopez D; Kemp-Casey A; Saunders C; Roughead E; Boyle F; Bulsara M; Preen D
    Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of patients with hormone receptor-positive breast cancer who need adjuvant tamoxifen therapy for more than 5 years.
    Wu CE; Chen SC; Chang HK; Lo YF; Hsueh S; Lin YC
    J Formos Med Assoc; 2016 Apr; 115(4):249-56. PubMed ID: 25900861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain.
    Font R; Espinas JA; Barnadas A; Izquierdo A; Galceran J; Saladie F; Marcos-Gragera R; Torrent A; Manchon-Walsh P; Borras JM
    Breast Cancer Res Treat; 2019 Jun; 175(3):733-740. PubMed ID: 30887164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study.
    Hjorth CF; Nielsen AS; Sørensen HT; Lash TL; Damkier P; Hamilton-Dutoit S; Cronin-Fenton D
    Acta Oncol; 2019 Feb; 58(2):168-174. PubMed ID: 30458661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17.
    Goodwin RA; Jamal R; Booth CM; Goss PE; Eisenhauer EA; Tu D; Shepherd LE
    Eur J Cancer; 2016 May; 58():97-103. PubMed ID: 26986765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Obesity and endocrine therapy: host factors and breast cancer outcome.
    Goodwin PJ
    Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis.
    Gligorov J; Pritchard K; Goss P
    Breast; 2007 Dec; 16 Suppl 3():S1-9. PubMed ID: 18061455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Managing side effects in adjuvant endocrine therapy for breast cancer.
    Condorelli R; Vaz-Luis I
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1101-1112. PubMed ID: 30188738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adherence rates and correlates in long-term hormonal therapy.
    Dunn J; Gotay C
    Vitam Horm; 2013; 93():353-75. PubMed ID: 23810015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Good adherence to adjuvant endocrine therapy in early breast cancer - a population-based study based on the Swedish Prescribed Drug Register.
    Lundgren C; Lindman H; Rolander B; Ekholm M
    Acta Oncol; 2018 Jul; 57(7):935-940. PubMed ID: 29493327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.
    Blanchette PS; Lam M; Richard L; Allen B; Shariff SZ; Vandenberg T; Pritchard KI; Chan KKW; Louie AV; Desautels D; Raphael J; Earle CC
    Breast Cancer Res Treat; 2020 Jan; 179(1):217-227. PubMed ID: 31571072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Which women decide to take tamoxifen?
    Narod SA; Sopik V; Sun P
    Breast Cancer Res Treat; 2017 Jul; 164(1):149-155. PubMed ID: 28374324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ.
    Zhao H; Hei N; Wu Y; Chan W; Lei X; Cameron C; Chang S; Chavez-MacGregor M; Giordano SH
    Cancer; 2017 May; 123(6):940-947. PubMed ID: 27780311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors.
    Brier MJ; Chambless DL; Chen J; Mao JJ
    Eur J Cancer; 2018 Mar; 91():145-152. PubMed ID: 29329697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality.
    Makubate B; Donnan PT; Dewar JA; Thompson AM; McCowan C
    Br J Cancer; 2013 Apr; 108(7):1515-24. PubMed ID: 23519057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.